- Details
- Description
Packaging Size:
30 tablets per pack for the 100 mg presentation.
Strength:
100 mg and 150 mg
Composition:
Each film-coated tablet contains daraxonrasib.
Treatment:
Targeted anticancer therapy; RAS(ON) inhibitor used for eligible adults with metastatic pancreatic adenocarcinoma.
Form:
Film-coated tablets
Brand:
LuciDarax
Quantity Unit:
Tablets
Manufacturer:
Lucius Pharmaceuticals (Lao) Ltd.
LuciDarax (daraxonrasib/RMC-6236) is an oral targeted anticancer medicine containing daraxonrasib, a RAS(ON) inhibitor designed to block abnormal RAS signaling involved in cancer cell growth. It is used/investigated for RAS-driven solid tumors, particularly metastatic pancreatic cancer. LuciDarax is available in tablet strengths such as 100 mg and 150 mg.
